Aaron S. Kesselheim

Brigham and Women's Hospital/Harvard Medical School

Professor of Medicine

1620 Tremont St

Suite 3030

Boston, MA 02120

United States

http://www.PORTALresearch.org

SCHOLARLY PAPERS

31

DOWNLOADS
Rank 20,577

SSRN RANKINGS

Top 20,577

in Total Papers Downloads

2,331

SSRN CITATIONS
Rank 21,372

SSRN RANKINGS

Top 21,372

in Total Papers Citations

6

CROSSREF CITATIONS

29

Scholarly Papers (31)

1.

Using Antitrust Law to Challenge Turing's Daraprim Price Increase

31 Berkeley Technology Law Journal 1379 (2017)
Number of pages: 30 Posted: 29 Jan 2016 Last Revised: 14 Jul 2017
Michael A. Carrier, Nicole Levidow and Aaron S. Kesselheim
Rutgers Law School, Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics and Brigham and Women's Hospital/Harvard Medical School
Downloads 652 (39,592)

Abstract:

Loading...

Turing, Shkreli, antitrust, monopolization, drugs, pharmaceuticals, Daraprim, pyrimethamine

2.

Effect of Financial Relationships on the Behaviors of Health Care Professionals: A Review of the Evidence

40 Journal of Law, Medicine, & Ethics 452 (2012), Arizona Legal Studies Discussion Paper No. 12-30
Number of pages: 44 Posted: 02 Aug 2012 Last Revised: 14 Apr 2013
Christopher T. Robertson, Susannah L. Rose and Aaron S. Kesselheim
University of Arizona - James E. Rogers College of Law, Cleveland Clinic, Department of Bioethics and Brigham and Women's Hospital/Harvard Medical School
Downloads 297 (102,818)

Abstract:

Loading...

incentives, conflicts of interest, medical decision making, bias, self-referral, industry, insurance, pay for performance

3.

Improving Antibiotic Markets for Long Term Sustainability

Yale Journal of Health Policy, Law & Ethics, Vol. 11, Winter 2011, Boston Univ. School of Law Working Paper (Law & Economics) No. 10-42, Boston Univ. School of Law Working Paper (Public Law & Legal Theory) No. 10-42
Number of pages: 71 Posted: 07 Dec 2010 Last Revised: 16 Apr 2013
Aaron S. Kesselheim and Kevin Outterson
Brigham and Women's Hospital/Harvard Medical School and Boston University School of Law
Downloads 282 (108,665)
Citation 1

Abstract:

Loading...

antibiotic, resistance, intellectual property, patent, conservation, prize

4.

Off-Label Drug Use and Promotion: Balancing Public Health Goals and Commercial Speech

American Journal of Law and Medicine, Vol. 37, No. 2-3, 2011
Number of pages: 33 Posted: 23 Mar 2014
Aaron S. Kesselheim
Brigham and Women's Hospital/Harvard Medical School
Downloads 214 (143,652)
Citation 2

Abstract:

Loading...

Prescription drug, FDA, off-label, pharmaceutical marketing

5.

Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980-2009

Journal of Law, Medicine and Ethics, p. 688, Fall 2013, Boston Univ. School of Law, Law and Economics Research Paper No. 13-47
Number of pages: 10 Posted: 18 Sep 2013 Last Revised: 08 Aug 2015
Boston University School of Law, George Washington University, Director International Center for Pharmaceutical Economics and Policy, University of Massachusetts and Brigham and Women's Hospital/Harvard Medical School
Downloads 204 (150,306)

Abstract:

Loading...

antibiotics, innovation, resistance

6.

Prospects for Regulation of Off-Label Drug Promotion in an Era of Expanding Commercial Speech Protection

North Carolina Law Review, Vol. 92, 2014
Number of pages: 62 Posted: 20 Mar 2014
Aaron S. Kesselheim and Michelle M. Mello
Brigham and Women's Hospital/Harvard Medical School and Stanford Law School
Downloads 160 (186,758)

Abstract:

Loading...

FDA, regulation, commercial speech, First Amendment, off-label, prescription drug

7.

Pharmaceutical Marketing and the New Social Media

New England Journal of Medicine, Vol. 363, No. 22, pp. 2087-2089, 2010
Number of pages: 3 Posted: 21 Dec 2011
Jeremy A. Greene and Aaron S. Kesselheim
Harvard University - Department of the History of Science and Brigham and Women's Hospital/Harvard Medical School
Downloads 132 (218,712)

Abstract:

Loading...

8.

Blinding as a Solution to Bias: Strengthening Biomedical Science, Forensic Science, and Law

Blinding as a Solution to Bias: Strengthening Biomedical Science, Forensic Science, and Law (Elsevier 2016), Arizona Legal Studies Discussion Paper No. 16-03
Number of pages: 20 Posted: 08 Feb 2016
Christopher T. Robertson and Aaron S. Kesselheim
University of Arizona - James E. Rogers College of Law and Brigham and Women's Hospital/Harvard Medical School
Downloads 88 (290,327)

Abstract:

Loading...

blinding, bias, forensic science, scientific research, courts, medicine, biomedical science

9.

Generic But Expensive: Why Prices Can Remain High for Off-Patent Drugs

Hastings Law Journal, Forthcoming (Volume 71, Issue 4, May 2020)
Number of pages: 25 Posted: 21 Aug 2019 Last Revised: 17 Oct 2019
Frazer Tessema, Aaron S. Kesselheim and Michael S. Sinha
Program On Regulation, Therapeutics, And Law (PORTAL), Brigham & Women's Hospital / Harvard Medical School, Brigham and Women's Hospital/Harvard Medical School and Harvard-MIT Center for Regulatory Science, Harvard Medical School
Downloads 86 (294,564)

Abstract:

Loading...

Food and Drug Administration, FDA, Drug Prices, Generic Drugs, Importation, Drug Shortages, Off-Patent Drugs, Niche Markets

10.

Implementing a Public Health Perspective in FDA Drug Regulation

Food and Drug Law Journal, Vol. 73, pp. 221-256, 2018, Georgia State University College of Law, Legal Studies Research Paper No. 2018-21
Number of pages: 37 Posted: 11 Jun 2018 Last Revised: 27 Sep 2018
Patricia J. Zettler, Margaret Foster Riley and Aaron S. Kesselheim
Ohio State University (OSU) - Michael E. Moritz College of Law, University of Virginia School of Law and Brigham and Women's Hospital/Harvard Medical School
Downloads 82 (303,357)
Citation 1

Abstract:

Loading...

opioid, FDA, public health, public health law, health law, food and drug administration, drug regulation, drug approval, Food Drug and Cosmetic Act, opioid misuse, food and drug law, law, administrative law, agency

11.

How Medicare Could Get Better Prices On Prescription Drugs

Health Affairs, Vol. 28, No. 5, 2009
Number of pages: 10 Posted: 22 Nov 2009 Last Revised: 16 Apr 2013
Kevin Outterson and Aaron S. Kesselheim
Boston University School of Law and Brigham and Women's Hospital/Harvard Medical School
Downloads 59 (362,746)

Abstract:

Loading...

Drug costs, Medicare Part D, therapeutic substitution, drug importation

12.

Market-Based Licensing for HPV Vaccines in Developing Countries

Health Affairs, Vol. 27, No. 1, 2008
Number of pages: 14 Posted: 22 Nov 2009 Last Revised: 11 Feb 2014
Kevin Outterson and Aaron S. Kesselheim
Boston University School of Law and Brigham and Women's Hospital/Harvard Medical School
Downloads 31 (466,587)

Abstract:

Loading...

Compulsory license, HPV vaccine, generic open license, access to vaccines

13.

Fighting Antibiotic Resistance: Marrying New Financial Incentives to Meeting Public Health Goals

Health Affairs, Vol. 29, No. 9, September 2010 , Boston Univ. School of Law Working Paper No. 10-40
Number of pages: 8 Posted: 16 Nov 2010 Last Revised: 08 Aug 2015
Kevin Outterson and Aaron S. Kesselheim
Boston University School of Law and Brigham and Women's Hospital/Harvard Medical School
Downloads 27 (486,658)
Citation 1

Abstract:

Loading...

antibiotic resistance, antibiotics, drug development, patenting of antibiotics

14.

When Markets Fail: Patents and Infectious Disease Products

73(3) Food & Drug L J 361 (2018)
Number of pages: 26 Posted: 22 Aug 2019
Jonathan J. Darrow, Michael S. Sinha and Aaron S. Kesselheim
Harvard Medical School, Harvard-MIT Center for Regulatory Science, Harvard Medical School and Brigham and Women's Hospital/Harvard Medical School
Downloads 14 (562,278)

Abstract:

Loading...

15.

Characteristics of Trials and Regulatory Pathways Leading to US Approval of Innovative vs. Non-Innovative Oncology Drugs

Number of pages: 16 Posted: 05 Sep 2018
Kerstin Noƫlle Vokinger and Aaron S. Kesselheim
Harvard University - Brigham and Women's Hospital and Brigham and Women's Hospital/Harvard Medical School
Downloads 3 (635,334)

Abstract:

Loading...

first-generation drug, second-generation drug, tyrosine-kinase inhibitor, monoclonal antibody, drug approval, FDA

An 'Export-Only' Exception to Pharmaceutical Patents in Europe: Should the U.S. Follow Suit?

Nature Biotechnology, Vol. 37, No. 1, 03.01.2019, p. 21-22.
Posted: 24 Apr 2019
Timo Minssen, Aaron S. Kesselheim and Jonathan J. Darrow
University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law, Brigham and Women's Hospital/Harvard Medical School and Harvard Medical School

Abstract:

Loading...

An 'Export-Only' Exception to Pharmaceutical Patents in Europe: Should the U.S. Follow Suit?

Nature Biotechnology, Vol.37, No. 1, pp. 21-22 (2019); DOI: 10.1038/nbt.4324
Posted: 27 Jun 2019
Timo Minssen, Aaron S. Kesselheim and Jonathan J. Darrow
University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law, Brigham and Women's Hospital/Harvard Medical School and Harvard Medical School

Abstract:

Loading...

17.

'Government Patent Use': A Legal Approach to Reducing Drug Spending

Health Affairs, Vol. 35, No. 5, 2016
Posted: 05 May 2016
Amy Kapczynski and Aaron S. Kesselheim
Yale University - Law School and Brigham and Women's Hospital/Harvard Medical School

Abstract:

Loading...

Medicines, Drug Pricing, Government Use, Patents, 28 USC 1498, Cost of Health Care, Legal and Regulatory Issues, Pharmaceuticals

18.

FDA Regulation of Mobile Health Technologies

370 New England Journal of Medicine 372 (2014) , Harvard Public Law Working Paper No. 14-40
Posted: 22 Oct 2014 Last Revised: 04 Dec 2014
Nathan Cortez, I. Glenn Cohen and Aaron S. Kesselheim
Southern Methodist University - Dedman School of Law, Harvard Law School and Brigham and Women's Hospital/Harvard Medical School

Abstract:

Loading...

mobile health, FDA, liability, congress, premarket, postmarket

19.

Distributions of Industry Payments to Massachusetts Physicians

New England Journal of Medicine, 2013, Arizona Legal Studies Discussion Paper No. 12-27
Posted: 07 May 2013 Last Revised: 22 May 2013
Brigham and Women's Hospital/Harvard Medical School, University of Arizona - James E. Rogers College of Law, Independent, Independent and Independent

Abstract:

Loading...

distributions of payments, payments to health care practitioners, industry payments

20.

A Randomized Study of How Physicians Interpret Research Funding Disclosures

369 New England Journal of Medicine 1119 (2012), Arizona Legal Studies Discussion Paper No. 12-33
Posted: 20 Oct 2012
Brigham and Women's Hospital/Harvard Medical School, University of Arizona - James E. Rogers College of Law, Harvard University - Brigham and Women's Hospital, Cleveland Clinic, Department of Bioethics, Harvard University - Brigham and Women's Hospital, American Board of Internal Medicine (ABIM), Harvard University - Brigham and Women's Hospital, Dana-Farber Cancer Center and Harvard University - Brigham and Women's Hospital

Abstract:

Loading...

clinical trial funding, trial results, industry sponsorship

21.

Why Do the Same Drugs Look Different? Pills, Trade Dress, and Public Health

New England Journal of Medicine, Vol. 365, No. 1, pp. 83-89, 2011
Posted: 21 Dec 2011
Jeremy A. Greene and Aaron S. Kesselheim
Harvard University - Department of the History of Science and Brigham and Women's Hospital/Harvard Medical School

Abstract:

Loading...

22.

Using Market Exclusivity Incentives to Promote Pharmaceutical Innovation

New England Journal of Medicine, Vol. 363, No. 19, pp. 1855-1862, 2010
Posted: 10 Nov 2010
Aaron S. Kesselheim
Brigham and Women's Hospital/Harvard Medical School

Abstract:

Loading...

patent, orphan drug, Bayh-Dole, pediatric exclusivity

23.

Whistleblower-Initiated Enforcement Actions Against Health Care Fraud and Abuse in the United States, 1996 to 2005

Annals of Internal Medicine, Vol. 149, No. 5, pp. 342-349, September 2008
Posted: 22 Nov 2009
Aaron S. Kesselheim and David M. Studdert
Brigham and Women's Hospital/Harvard Medical School and University of Melbourne - Faculty of Law & Faculty of Medicine, Dentistry and Health Sciences

Abstract:

Loading...

Health care fraud, qui tam, whistleblowers, pharmaceutical industry

24.

Expert Review of Drug Patent Applications: Improving Health in the Developing World

Health Affairs, Vol. 28, No. 5, 2009
Posted: 22 Nov 2009
Tahir Amin, Rahul Rajkumar, Priti Radhakrishnan and Aaron S. Kesselheim
Initiative for Medicines, Access & Knowledge (I-MAK), Harvard University - Brigham and Women's Hospital, Initiative for Medicines, Access & Knowledge (I-MAK) and Brigham and Women's Hospital/Harvard Medical School

Abstract:

Loading...

patents, TDF, Indian patent act, TRIPS agreement

25.

Using Patent Data to Assess the Value of Pharmaceutical Innovation

Journal of Law, Medicine, and Ethics, Vol. 37, No. 2, 2009
Posted: 22 Nov 2009
Aaron S. Kesselheim and Jerry Avorn
Brigham and Women's Hospital/Harvard Medical School and Harvard University - Brigham and Women's Hospital

Abstract:

Loading...

patents, pharmaceutical, innovation

26.

Professional Oversight of Physician Expert Witnesses: An Analysis of Complaints to the Professional Conduct Committee of the American Association of Neurological Surgeons, 1992-2006

Annals of Surgery, Vol. 249, No. 1, pp. 168-172, 2009
Posted: 22 Nov 2009
Aaron S. Kesselheim and David M. Studdert
Brigham and Women's Hospital/Harvard Medical School and University of Melbourne - Faculty of Law & Faculty of Medicine, Dentistry and Health Sciences

Abstract:

Loading...

Expert witness, medical malpractice, medical professional society

27.

The International Pharmaceutical Market as a Source of Low-Cost Prescription Drugs for U.S. Patients

Annals of Internal Medicine, Vol. 148, No. 8, pp. 614-619, April 2008
Posted: 22 Nov 2009
Aaron S. Kesselheim and Niteesh K. Choudhry
Brigham and Women's Hospital/Harvard Medical School and Harvard University - Medical School

Abstract:

Loading...

Drug importation, generic drugs

University-Based Science and Biotechnology Products: Defining the Boundaries of Intellectual Property

JAMA, Vol. 293, pp. 850-854, 2005
Posted: 04 Dec 2006
Aaron S. Kesselheim and Jerry Avorn
Brigham and Women's Hospital/Harvard Medical School and Harvard University - Brigham and Women's Hospital

Abstract:

Loading...

Patent, Technology Transfer, Intellectual Property

University-Based Science and Biotechnology Products: Defining the Boundaries of Intellectual Property

University of Illinois at Urbana-Champaign's Academy for Entrepreneurial Leadership Historical Research Reference in Entrepreneurship
Posted: 18 Nov 2009
Aaron S. Kesselheim and Jerry Avorn
Brigham and Women's Hospital/Harvard Medical School and Harvard University - Brigham and Women's Hospital

Abstract:

Loading...

Patent pools, U.S. Patent & Trademark Office (USPTO), Colleges & universities, Commercialization, Intellectual property, Patent law, Patents, Pharmaceutical industry, Academic research, Arbitration, Bayh-Dole Act of 1980, Biotechnology industry, Scientists

29.

Extensions of Intellectual Property Rights and Delayed Adoption of Generic Drugs: Effects on Medicaid Expenditures

Health Affairs, Vol. 25, pp. 1637-1647, 2006
Posted: 04 Dec 2006
Aaron S. Kesselheim, Jerry Avorn and Michael Fischer
Brigham and Women's Hospital/Harvard Medical School, Harvard University - Brigham and Women's Hospital and Harvard University - Brigham and Women's Hospital

Abstract:

Loading...

Patent, Drug Costs, Intellectual Property, Generic Drugs

30.

The Rise and Fall of Natrecor for Congestive Heart Failure: Implications for Drug Policy

Health Affairs, Vol. 25, pp. 1095-1102, 2006
Posted: 04 Dec 2006
Aaron S. Kesselheim
Brigham and Women's Hospital/Harvard Medical School

Abstract:

Loading...

FDA, Drug policy, Post-marketing surveillance

31.

Medical Process Patents - Monopolizing the Delivery of Health Care

New England Journal of Medicine, Vol. 355, pp. 2036-2041, 2006
Posted: 09 Nov 2006
Aaron S. Kesselheim and Michelle M. Mello
Brigham and Women's Hospital/Harvard Medical School and Stanford Law School

Abstract:

Loading...

patents, medical, process, intellectual property